On Jan. 21, Avalanche announced the launch of the C-Chain round of Retro9000, the retroactive grant program that rewards up to $40 million to developers strengthening the Avalanche ecosystem. One of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results